Literature DB >> 9820875

Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2.

V A Smelt1, H J Mardon, E Sim.   

Abstract

The study of placental xenobiotic metabolism is important for the determination of foetal exposure to environmental chemicals as placental metabolism influences the nature of chemicals reaching the foetus from its mother's blood. Arylamine N-acetyltransferases are drug metabolizing enzymes which N-acetylate hydrazines and arylamines, including carcinogenic arylamines and sulphonamide drugs. The two human arylamine N-acetyltransferase isoenzymes, NAT1 and NAT2, are encoded at multi-allelic loci. Here, we have determined N-acetyltransferase (NAT) activity in term placentas from normal, uncomplicated pregnancies. Both NAT1 and NAT2 enzyme activities were detectable. Placental NAT1 activity was at least 1000 fold greater than NAT2 activity. There was a 6 fold inter-placental variation in NAT1 activity. Mean placental NAT1 specific activity was 1.42 nmoles para-aminobenzoic acid N-acetylated.min-1.mg protein-1, which is comparable to NAT1 specific activities which have been measured in adult tissues. The NAT1, but not the NAT2, protein was detectable in placentas by Western blotting. Maternal and foetal NAT genotypes were determined from placenta, using placental blood clots and cord blood respectively, allowing NAT haplotype determination. There appeared to be linkage disequilbrium between NAT1* and NAT2* alleles such that the combination NAT1*10/NAT2*4 was found 3.5 times more frequently than would be expected.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820875     DOI: 10.1111/j.1600-0773.1998.tb01461.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  10 in total

Review 1.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

2.  N-Acetyltransferase polymorphism and human cancer risk.

Authors:  X Yang; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

3.  Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.

Authors:  Donghui Li; Li Jiao; Yanan Li; Mark A Doll; David W Hein; Melissa L Bondy; Douglas B Evans; Robert A Wolff; Renato Lenzi; Peter W Pisters; James L Abbruzzese; Manal M Hassan
Journal:  Carcinogenesis       Date:  2005-06-29       Impact factor: 4.944

4.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

5.  Analysis of candidate modifier loci for the severity of colonic familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases.

Authors:  M D Crabtree; C Fletcher; M Churchman; S V Hodgson; K Neale; R K S Phillips; I P M Tomlinson
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 6.  Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review.

Authors:  David W Hein; Giannoulis Fakis; Sotiria Boukouvala
Journal:  Pharmacogenet Genomics       Date:  2018-10       Impact factor: 2.089

7.  NAT1 and NAT2 genetic polymorphisms and environmental exposure as risk factors for oesophageal squamous cell carcinoma: a case-control study.

Authors:  Marco Matejcic; Matjaz Vogelsang; Yabing Wang; M Iqbal Parker; Iqbal M Parker
Journal:  BMC Cancer       Date:  2015-03-18       Impact factor: 4.430

8.  Arylamine N-acetyltransferase 2 Polymorphisms and the Risk of Endometriosis.

Authors:  Diman Fayez; Kioomars Saliminejad; Shiva Irani; Koorosh Kamali; Toktam Memariani; Hamid Reza Khorram Khorshid
Journal:  Avicenna J Med Biotechnol       Date:  2018 Jul-Sep

9.  NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant.

Authors:  Nichola Johnson; Peter Bell; Vesna Jonovska; Marc Budge; Edith Sim
Journal:  BMC Med Genet       Date:  2004-03-17       Impact factor: 2.103

Review 10.  Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Authors:  E Sim; A Abuhammad; A Ryan
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.